GLP-1 and muscle

Resistance training and protein during a deficit: what the trials measured

Two separate research literatures get read as one. The first asks what resistance training and dietary protein do to lean mass and strength in adults losing weight. The second asks how much weight GLP-1 receptor agonists produce and what happens to body composition along the way. Different investigators, different populations, different outcomes. This article stays with what each one actually measured, and marks the join where no data exists.

What the protein meta-analysis measured

Morton and colleagues pooled randomised controlled trials in which protein supplementation was layered on top of supervised resistance training in healthy adults. The pooled effect on fat-free mass was positive and small: adding protein to a training programme produced a modest additional gain in lean mass, and a modest additional gain in one-repetition-maximum strength, compared with training plus a control supplement. The effect was consistent enough across trials to survive pooling, and small enough that it reads as an increment on top of training rather than a substitute for it.¹

The meta-regression in that paper is the part most often stripped of its context. It identified a breakpoint in total daily protein intake, in the region of 1.6 g per kilogram of body weight per day in the trial populations analysed, above which no further gain in fat-free mass was detected. That figure describes where the pooled dose–response curve flattened in the samples studied, which were largely younger, healthy, training adults. It is not a recommendation, not a target, and not something a general-purpose site can individualise. An intake appropriate for a particular person depends on kidney function, medications, body size, and clinical context, and comes from a qualified clinician or registered dietitian.¹

Energy deficit, lean mass, and strength

Murphy and Koehler pooled resistance-training trials conducted with and without an imposed energy deficit and asked a narrower question: does being in a deficit change what training produces? Their answer separated two outcomes that are usually spoken about together. Energy deficiency attenuated training-induced gains in lean mass. It did not measurably attenuate gains in strength.²

That dissociation matters when reading a scale or a DXA report. If lean-mass accrual is the outcome most sensitive to energy availability, then a flat or falling lean-mass estimate during weight loss is partly a statement about energy balance rather than a verdict on whether the training stimulus is working. Strength, in the pooled data, kept improving. Someone can be getting stronger while a body-composition estimate moves in an unflattering direction, and neither number alone establishes which tissue changed.²

• Lean mass and strength are different outcomes, and they responded differently to energy availability in the pooled analysis.
• A DXA or bioimpedance estimate carries its own measurement error, which does not shrink because the reading is inconvenient.
• Neither measure identifies why weight changed, and no tracker can make that determination.²³

The older systematic review by Weinheimer and colleagues asked the prior question in middle-aged and older adults: what happens to fat-free mass under energy restriction alone, compared with energy restriction plus exercise? Across the studies reviewed, energy restriction reduced fat-free mass alongside fat mass, and adding exercise generally reduced the fat-free-mass share of the loss rather than abolishing it. The review was framed around sarcopenic obesity, and none of its participants were taking weight-loss pharmacotherapy.³

The randomised trial run inside a deficit

Longland and colleagues ran the trial cited most often in this conversation, and it is worth reading for its design rather than its headline. Young men were placed in a steep, controlled energy deficit for four weeks and randomised to a higher or a lower dietary protein intake while completing a supervised, near-daily programme of resistance and high-intensity exercise. Food was provided. Training was supervised. Compliance was not left to chance.⁴

The higher-protein group finished the four weeks with more lean mass and less fat mass than the lower-protein group. Both intakes assigned in that trial sat above typical habitual intake, and the higher arm sat above the breakpoint identified in the meta-regression described earlier. Those figures describe what investigators administered to a small group of young men under supervision for one month. They are not a plan, and they say nothing about what any particular reader should eat while taking a medication. That decision belongs to a qualified professional who knows the individual case.⁴

Cava, Yeat, and Mittendorfer place these findings in the wider picture of muscle during weight loss, including the observation that some loss of lean tissue accompanies substantial fat loss more or less unavoidably, and that not all of the lean tissue lost is contractile muscle. Water, glycogen, and connective tissue move with it, which is one reason a single body-composition number is a blunt instrument.⁵

The join that was never made

STEP 1 and SURMOUNT-1 established the weight-loss effects of once-weekly semaglutide and tirzepatide over 68 and 72 weeks respectively. In both, every participant, on drug and on placebo, received lifestyle counselling that included a reduced-calorie diet and a physical-activity target. That is background care applied equally across arms, not a randomised training intervention. Body-composition measurements in these programmes were made in subsets, using imaging, and were not designed to test whether training changed the composition of the weight lost.⁶⁷

The consequence is specific rather than vague. Nobody was randomised to lift or not to lift while taking these drugs. The training literature can describe what supervised training did in people dieting without a GLP-1; the drug trials can describe how much weight came off with counselling as background. No published randomised trial has crossed the two.⁶⁷

What the semaglutide trials reported about weight and body composition, with the substudy limits stated.

Appetite suppression is its own confound

There is a second, quieter problem. The protein intakes reached in the training trials were reached by people with intact appetites, frequently with food supplied by the investigators. GLP-1 receptor agonists work in large part by reducing energy intake. A reduction in total intake tends to reduce absolute protein intake unless the composition of what remains shifts, and early satiety, nausea, and altered food preferences all push in the same direction.⁵

So the intakes that produced the effects in the meta-analysis and in the randomised trial may be harder to reach for someone whose appetite is pharmacologically blunted. That is a plausible mechanism, not a measured finding. No trial has quantified achieved protein intake in GLP-1 users against the intakes used in the training literature, and none has tested whether the lean-mass effect of higher protein survives at the intakes people on these drugs actually manage.¹⁴

Given the dissociation Murphy and Koehler reported, a strength log and a body-composition estimate answer different questions, and it is reasonable to keep both rather than letting one stand in for the other. What neither can do is establish causality.²

• A scale trend records total weight and nothing about tissue.
• A body-composition estimate records what one device inferred, under its own conditions, on one day.
• A training log records what was completed, which is the input most directly under your control.
• Bring the pattern, not a conclusion, to the clinician managing your treatment.

Common questions